Holen Sie sich die Stockscreener-App
20.59
2.59%
0.52
Schlusskurs vom Vortag:
$20.07
Offen:
$20.26
24-Stunden-Volumen:
396.16K
Relative Volume:
1.23
Marktkapitalisierung:
$1.27B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-209.84M
KGV:
-4.5055
EPS:
-4.57
Netto-Cashflow:
$-6.73M
1W Leistung:
-1.77%
1M Leistung:
-16.30%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$19.49
$21.02
1-Wochen-Bereich:
$18.59
$21.89
52-Wochen-Spanne:
$16.50
$28.76
Damora Therapeutics Inc Stock (DMRA) Company Profile
Firmenname
Damora Therapeutics Inc
Sektor
Branche
Telefon
(781) 281-9020
Adresse
221 CRESCENT STREET, WALTHAM
Compare DMRA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DMRA
Damora Therapeutics Inc
|
20.59 | 1.24B | 0 | -209.84M | -6.73M | -4.57 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Damora Therapeutics Inc Stock (DMRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-24 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2026-03-25 | Eingeleitet | Evercore ISI | Outperform |
| 2026-02-17 | Eingeleitet | UBS | Buy |
| 2026-01-07 | Eingeleitet | Leerink Partners | Outperform |
| 2025-12-01 | Eingeleitet | Guggenheim | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-11-23 | Eingeleitet | BofA Securities | Buy |
| 2020-11-23 | Eingeleitet | Credit Suisse | Outperform |
| 2020-11-23 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Damora Therapeutics Inc Aktie (DMRA) Neueste Nachrichten
Damora Therapeutics, Inc. Common Stock (DMRA) Stock Trends and Sentiment 2026 - MarketBeat
DMRA Q1 2026 Earnings: EPS Misses Estimates as Clinical Costs WeighEPS Guidance Update - newsline.com
Damora Therapeutics, Inc. Common Stock (DMRA) Institutional Ownership 2026 - MarketBeat
Top Damora Therapeutics, Inc. Common Stock (DMRA) Competitors 2026 - MarketBeat
DMRA Reiterates by Wedbush -- Price Target Maintained at $35 - GuruFocus
Damora Therapeutics, Inc. Common Stock (DMRA) Stock Chart and Price History 2026 - MarketBeat
DMRA Initiated Coverage by HC Wainwright & Co. -- Price Target S - GuruFocus
Damora Therapeutics, Inc. Common Stock (DMRA) Earnings Date and Reports 2026 - MarketBeat
TD Cowen initiates Damora Therapeutics stock rating at Buy - Investing.com UK
TD Cowen initiates Damora Therapeutics stock rating at Buy By Investing.com - Investing.com India
Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge - AOL.com
Damora Therapeutics Inc (DMRA) SEC filings - GuruFocus
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
FCPM III Services Buys 2.44 Million Shares of Damora Therapeutics - asatunews.co.id
FCPM III Services Acquires Millions of Damora Therapeutics Shares - HarianBasis.co
Damora Therapeutics, Inc.Common Stock (Nasdaq:DMRA) Stock Quote - The Chronicle-Journal
DMRA Q1 2026 Earnings: EPS Misses Estimates by a Wide MarginSubscription Growth Report - newsline.com
Damora Therapeutics (DMRA) Receives Outperform Rating and $35 Ta - GuruFocus
DMRA Initiated by Wedbush -- Price Target Announced at $35.00 - GuruFocus
DMRA Q1 2026 Earnings: EPS Misses Estimates by Over 50%, Stock SlipsOne-Time Gain Impact - newsline.com
DMRA Technical Analysis & Stock Price Forecast - Intellectia AI
DMRA Q1 2026 Earnings: Wider-Than-Expected Loss Sends Shares LowerQuarterly Profit Report - The Legal Advocate
Damora Therapeutics: Well-Funded Moonshot For CALR Mutations (NASDAQ:DMRA) - Seeking Alpha
Damora Therapeutics (DMRA) Gains 2.4% as Biotech Sector Finds FootingTriple Bottom - newsline.com
Damora Therapeutics (DMRA) Holds Steady Near Support: Technical Analysis of Key LevelsAnalyst Downgrade Signals - The Legal Advocate
Damora Therapeutics Holds Steady Near Key Support Amid Quiet TradingAdaptive Moving Average - The Legal Advocate
Damora Therapeutics’ Deepening Losses Raise a Quiet Question About Its Cost Strategy and Runway (DMRA) - simplywall.st
Finanzdaten der Damora Therapeutics Inc-Aktie (DMRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Damora Therapeutics Inc-Aktie (DMRA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | Director |
Feb 09 '26 |
Option Exercise |
0.00 |
8,713,000 |
0 |
5,809,000 |
| Schambye Hans T. | Chief Executive Officer |
Jan 02 '26 |
Sale |
21.38 |
700 |
14,966 |
4,682 |
| Winslow Garrett | General Counsel |
Jan 02 '26 |
Sale |
21.38 |
255 |
5,452 |
1,854 |
| Firmani Lori | Chief Financial Officer |
Jan 02 '26 |
Sale |
21.41 |
135 |
2,890 |
931 |
| Schambye Hans T. | Chief Executive Officer |
Jul 03 '25 |
Sale |
3.38 |
735 |
2,484 |
4,022 |
| Winslow Garrett | General Counsel |
Jul 03 '25 |
Sale |
3.39 |
260 |
881 |
1,429 |
| Firmani Lori | Interim CFO |
Jul 03 '25 |
Sale |
3.39 |
147 |
498 |
692 |
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):